In contrast to the other procedures recommended for de-implementation by the CW campaign, providers have proven resistant to championing the final guideline for females with breast cancer aged ≥ 70 years.30 Likewise, these data demonstrate the majority (84.9%) of MBC patients ≥ 70 years of age with early-stage clinically node-negative, HR+, HER2− cancer underwent some form of LN intervention. This evidence concerns the gene ERBB2 and breast cancer.